)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
AC Immune
AC Immune (ACIU) investor relations material
AC Immune Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary5 Aug, 2026
Executive summary
Advanced clinical pipeline with key wholly-owned programs nearing major data readouts in H2 2026, including ACI-7104 in Parkinson's and ACI-19764 for neuroinflammation.
Partnered programs with Takeda and Lilly generated significant milestone payments, supporting financial stability.
Cash resources of CHF 75.4 million as of June 30, 2026, expected to fund operations into Q4 2027.
Financial highlights
Total revenue for H1 2026 was CHF 16.2 million, up from CHF 2.3 million in H1 2025, driven by milestone payments from Lilly (CHF 11.0 million) and Takeda (CHF 5.2 million).
R&D expenses decreased to CHF 22.2 million from CHF 32.7 million year-over-year, reflecting pipeline focus and lower operational spend.
Net loss narrowed to CHF 12.9 million from CHF 40.2 million year-over-year.
Cash and short-term financial assets totaled CHF 75.4 million at June 30, 2026.
Outlook and guidance
Full results from Part 1 of the Phase 2 VacSYn trial in Parkinson's disease expected in H2 2026.
Initial Phase 1 and 1b results for ACI-19764 NLRP3 inhibitor anticipated in H2 2026.
Lead declaration for Morphomer a-syn aggregation inhibitor expected in H2 2026.
Cash runway projected into Q4 2027, excluding additional milestone payments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AC Immune
- Precision prevention pipeline advances with strong clinical data and major pharma partnerships.ACIU
Investor presentation - Milestone payments and clinical progress support improved financials and outlook for 2026.ACIUQ1 2026
- Precision prevention pipeline advances disease-modifying therapies for neurodegenerative diseases.ACIUInvestor presentation
- Precision prevention pipeline advances in neurodegeneration with strong clinical and financial momentum.ACIUInvestor presentation
- Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027.ACIUQ4 2025
- Registering up to $350M in securities to fund neurodegenerative precision medicine pipeline.ACIURegistration Filing
- Precision medicine and immunotherapy pipeline advances with major data readouts due by year-end.ACIUJefferies London Healthcare Conference 2025
- Robust pipeline and partnerships drive progress in neurodegeneration and precision medicine.ACIUJefferies London Healthcare Conference 2024
- Major CNS pipeline advances, highlighted by a $2.1B Takeda deal and strong immunotherapy progress.ACIUJefferies 2024 Global Healthcare Conference
Next AC Immune earnings date
Q3 20264 Nov, 2026
AC Immune
Next AC Immune earnings date
Q3 20264 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage